Aktive Positionen von Ping Zhu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Direktor/Vorstandsmitglied | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.08.2021 | - | |
| Präsident | 01.08.2021 | - | |
| Corporate Officer/Principal | 01.01.2012 | 30.08.2021 |
Karriereverlauf von Ping Zhu
Ausbildung von Ping Zhu
| Shanghai Second Medical University | Undergraduate Degree |
| University of Karlsruhe | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 2 |
| China | 2 |
| Deutschland | 2 |
Operativ
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
